Results 21 to 30 of about 72,730 (267)

Evaluation of the use of chlorpromazine for agitation in pediatric patients [PDF]

Mental Health Clinician, 2023
Introduction: Chlorpromazine is a first-generation antipsychotic used for behavioral problems in pediatric patients. However, other therapies may demonstrate both improved outcomes and fewer side effects.
Rajwoana Ahmed, PharmD, Megan Maroney, PharmD, BCPP, Germin Fahim, PharmD, BCPS, Hoytin Lee Ghin, PharmD, BCPS, Andrew Scott Mathis, PharmD   +4 more
doaj   +1 more source

Risk factors for bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae

Brazilian Journal of Infectious Diseases, 2011
The objective of this study was to identify risk factors for bacteremia by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae.
Olivia Ferrández Quirante, PhD, PharmD, Santiago Grau Cerrato, PhD, PharmD, Sonia Luque Pardos, PhD, PharmD   +2 more
doaj   +1 more source

Reduced-dose carmustine (300 mg/m2) and melphalan as a conditioning regimen in multiple myeloma patients with CNS involvement: A case series

Current Problems in Cancer: Case Reports, 2023
Single-agent melphalan remains the gold standard for conditioning chemotherapy prior to autologous stem cell transplantation (ASCT) in the multiple myeloma (MM) setting. Melphalan's distribution in the central nervous system (CNS) is limited which raises
Garrett Rueda, Eric Smith, Nicolas De Padova, Hayley Heers, Ivan Komerdelj   +4 more
doaj   +1 more source

Impact of psychiatric pharmacist-led ambulatory alcohol withdrawal management [PDF]

Mental Health Clinician
Introduction Alcohol withdrawal syndrome (AWS) is a complication of alcohol use disorder commonly encountered across various healthcare settings. Management of AWS is routinely conducted in the inpatient setting; however, in numerous patients, ambulatory
Maxwell Lamb, PharmD, BCPS, Michelle Colvard, PharmD, BCPP, Jonathan Lister, PharmD, BCPP, Eric Johnson, PharmD, BCPP   +3 more
doaj   +1 more source

Use of a trigger tool to detect adverse drug reactions in an emergency department

BMC Pharmacology and Toxicology, 2017
Background Although there are systems for reporting adverse drug reactions (ADR), these safety events remain under reported. The low-cost, low-tech trigger tool method is based on the detection of events through clues, and it seems to increase the ...
Silvana Maria de Almeida, Aruana Romualdo, Andressa de Abreu Ferraresi, Giovana Roberta Zelezoglo, Alexandre R. Marra, Michael B. Edmond   +5 more
doaj   +1 more source

Teaching Deprescribing and Combating Polypharmacy in the Pharmacy Curriculum: Educational Recommendations from Thematic Analysis of Focus Groups

Clinics and Practice, 2023
In the last two decades in the United States (US), the previous research has focused on medication optimization, including polypharmacy. Polypharmacy is associated with several negative outcomes, which may be resolved by deprescribing medications that ...
Devin Scott, Alina Cernasev, Rachel E. Barenie, Sydney P. Springer, David R. Axon   +4 more
doaj   +1 more source

Multilevel Engagements of Pharmacists During the COVID-19 Pandemic: The Way Forward

Frontiers in Public Health, 2020
Severe acute respiratory syndrome caused by the novel coronavirus (SARS-CoV-2) was first reported in China in December 2019 which was later declared to be a public health emergency of international concern by the World Health Organization (WHO).
Tauqeer Hussain Mallhi, Aroosa Liaqat, Arooj Abid, Yusra Habib Khan, Nasser Hadal Alotaibi, Abdulaziz Ibrahim Alzarea, Nida Tanveer, Tahir Mehmood Khan   +7 more
doaj   +1 more source

Health‐Related Quality of Life and Symptom Severity Among Patients With PIK3CA‐Related Overgrowth Spectrum: A Mixed‐Methods Study to Understand Real‐World Experience With Alpelisib Treatment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background PIK3CA‐related overgrowth spectrum (PROS) includes several rare overgrowth disorders resulting from somatic gain‐of‐function mutations in PIK3CA. Despite treatment advances, including the recent approval of alpelisib for PROS in the United States, literature detailing the patient experience with PROS is limited.
Vamsi Bollu, Kaitlin LaGasse, Cory D. Saucier, Kimberly Raymond, Miranda Lauher‐Charest, Lauren Crowder, Beilei Cai, Mary Lisha Paul, Denise Adams   +8 more
wiley   +1 more source

The impact of hospital-based post-discharge pharmacist medication review on patient clinical outcomes: A systematic review

Exploratory Research in Clinical and Social Pharmacy, 2023
Background: Clinical pharmacists have been shown to identify and resolve medication related problems post-discharge, however the impact on patient clinical outcomes is unclear.
Jaclyn Costello, Michael Barras, Holly Foot, Neil Cottrell   +3 more
doaj   +1 more source

Hospitalization Through Families’ Eyes: Comparing Inpatient Care Quality for Children With Sickle Cell Disease and Cystic Fibrosis in Canada

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Sickle cell disease (SCD) is a chronic, inherited hemoglobinopathy that requires frequent hospitalization for disease‐related complications. Canadian data on inpatient care is limited. This study compared caregiver‐reported hospital experiences of children with SCD to those with cystic fibrosis (CF), a chronic, autosomal recessive ...
Hailey M. Zwicker, Kyle Kemp, Perri Tutelman, Sharon H. J. Hou, Paul Fairie, Maria Santana, Gregory M. T. Guilcher, Taryn Fay‐McClymont, Glenda Bendiak, Wendy Pelletier, Nicola Wright, Fiona Schulte   +11 more
wiley   +1 more source